Global Genomics

Global Genomics Group (G3) is a precision medicine company focused on the development of diagnostic tools and therapeutic targets for cardiovascular and metabolic diseases. The company utilizes a proprietary multi-omics platform that integrates whole-genome sequencing, transcriptomics, proteomics, metabolomics, and lipidomics data from large patient cohorts. Their flagship initiative, the GLOBAL study, is one of the largest pan-omics assessments of atherosclerosis, aimed at identifying novel biomarkers and pathways. G3 collaborates with pharmaceutical partners to translate these biological insights into targeted therapies and personalized diagnostic tests. The company's approach leverages advanced bioinformatics and artificial intelligence to decode complex disease mechanisms and improve patient outcomes.